Attovia Therapeutics priced its upsized IPO at $17 per share on August 4, 2026, raising $289 million in gross proceeds at a $731.5 million valuation, reflecting robust investor demand for its ATTOBODY platform targeting immune-mediated conditions. Shares debuted on Nasdaq under ticker ATTO on August 5 and rose sharply in early trading, reaching levels that imply a closing market capitalization near $942 million. This outcome aligns with the market-implied odds of 100% for the $900 million–$1 billion range, driven by the company’s recent Series C financing, clinical-stage pipeline momentum, and favorable biotech IPO sentiment. Scenarios that could still alter the final closing figure include last-minute order flow shifts, broader market volatility affecting small-cap biotechs, or underwriter stabilization activity around the greenshoe option.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · AktualisiertAttovia Therapeutics IPO Closing Marktkapitalisierung
Attovia Therapeutics IPO Closing Marktkapitalisierung
900 Mio. $–1 Mrd. $ 100.0%
<600 Mio. $ <1%
600 Mio. $–700 Mio. $ <1%
700 Mio. $–800 Mio. $ <1%
$1,858 Vol.
$1,858 Vol.
5. Aug. 2026
<600 Mio. $
Nein
600 Mio. $–700 Mio. $
Nein
700 Mio. $–800 Mio. $
Nein
800 Mio. $ - 900 Mio. $
Nein
900 Mio. $–1 Mrd. $
Ja
1 Mrd.+$
Nein
Kein Börsengang vor Oktober 2026
Nein
900 Mio. $–1 Mrd. $ 100.0%
<600 Mio. $ <1%
600 Mio. $–700 Mio. $ <1%
700 Mio. $–800 Mio. $ <1%
$1,858 Vol.
$1,858 Vol.
5. Aug. 2026
<600 Mio. $
$163 Vol.
Nein
600 Mio. $–700 Mio. $
$414 Vol.
Nein
700 Mio. $–800 Mio. $
$238 Vol.
Nein
800 Mio. $ - 900 Mio. $
$50 Vol.
Nein
900 Mio. $–1 Mrd. $
$270 Vol.
Ja
1 Mrd.+$
$553 Vol.
Nein
Kein Börsengang vor Oktober 2026
$170 Vol.
Nein
This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Attovia Therapeutics priced its upsized IPO at $17 per share on August 4, 2026, raising $289 million in gross proceeds at a $731.5 million valuation, reflecting robust investor demand for its ATTOBODY platform targeting immune-mediated conditions. Shares debuted on Nasdaq under ticker ATTO on August 5 and rose sharply in early trading, reaching levels that imply a closing market capitalization near $942 million. This outcome aligns with the market-implied odds of 100% for the $900 million–$1 billion range, driven by the company’s recent Series C financing, clinical-stage pipeline momentum, and favorable biotech IPO sentiment. Scenarios that could still alter the final closing figure include last-minute order flow shifts, broader market volatility affecting small-cap biotechs, or underwriter stabilization activity around the greenshoe option.
This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Markt eröffnet: Aug 4, 2026, 9:51 PM ET
Volumen
$1,858Enddatum
5. Aug. 2026Markt eröffnet
Aug 4, 2026, 9:51 PM ETResolver
0x69c47De9D...Vorgeschlagenes Ergebnis: Nein
Kein Einspruch
Endgültiges Ergebnis: Nein
This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Attovia Therapeutics priced its upsized IPO at $17 per share on August 4, 2026, raising $289 million in gross proceeds at a $731.5 million valuation, reflecting robust investor demand for its ATTOBODY platform targeting immune-mediated conditions. Shares debuted on Nasdaq under ticker ATTO on August 5 and rose sharply in early trading, reaching levels that imply a closing market capitalization near $942 million. This outcome aligns with the market-implied odds of 100% for the $900 million–$1 billion range, driven by the company’s recent Series C financing, clinical-stage pipeline momentum, and favorable biotech IPO sentiment. Scenarios that could still alter the final closing figure include last-minute order flow shifts, broader market volatility affecting small-cap biotechs, or underwriter stabilization activity around the greenshoe option.
This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volumen
$1,858Enddatum
5. Aug. 2026Markt eröffnet
Aug 4, 2026, 9:51 PM ETResolver
0x69c47De9D...Vorgeschlagenes Ergebnis: Nein
Kein Einspruch
Endgültiges Ergebnis: Nein
Attovia Therapeutics priced its upsized IPO at $17 per share on August 4, 2026, raising $289 million in gross proceeds at a $731.5 million valuation, reflecting robust investor demand for its ATTOBODY platform targeting immune-mediated conditions. Shares debuted on Nasdaq under ticker ATTO on August 5 and rose sharply in early trading, reaching levels that imply a closing market capitalization near $942 million. This outcome aligns with the market-implied odds of 100% for the $900 million–$1 billion range, driven by the company’s recent Series C financing, clinical-stage pipeline momentum, and favorable biotech IPO sentiment. Scenarios that could still alter the final closing figure include last-minute order flow shifts, broader market volatility affecting small-cap biotechs, or underwriter stabilization activity around the greenshoe option.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert
Vorsicht bei externen Links.
Vorsicht bei externen Links.
Häufig gestellte Fragen